Gary S. Gillheeney Sells 55,615 Shares of Organogenesis Holdings Inc. (NASDAQ:ORGO) Stock

Organogenesis Holdings Inc. (NASDAQ:ORGO) CEO Gary S. Gillheeney sold 55,615 shares of the stock in a transaction that occurred on Friday, December 13th. The stock was sold at an average price of $3.36, for a total value of $186,866.40. Following the completion of the transaction, the chief executive officer now directly owns 3,044,779 shares in the company, valued at approximately $10,230,457.44. This trade represents a 1.79 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.

Organogenesis Price Performance

Shares of ORGO stock opened at $3.57 on Wednesday. Organogenesis Holdings Inc. has a twelve month low of $2.16 and a twelve month high of $4.70. The company has a current ratio of 3.09, a quick ratio of 2.74 and a debt-to-equity ratio of 0.21. The stock has a fifty day simple moving average of $3.45 and a two-hundred day simple moving average of $3.01. The stock has a market capitalization of $473.30 million, a price-to-earnings ratio of -59.50 and a beta of 1.73.

Organogenesis (NASDAQ:ORGO) last released its quarterly earnings data on Tuesday, November 12th. The company reported $0.09 earnings per share for the quarter, beating the consensus estimate of ($0.02) by $0.11. Organogenesis had a negative return on equity of 2.69% and a negative net margin of 1.62%. The firm had revenue of $115.18 million during the quarter, compared to the consensus estimate of $109.59 million. During the same period in the previous year, the company posted $0.02 earnings per share. On average, analysts predict that Organogenesis Holdings Inc. will post -0.07 EPS for the current fiscal year.

Institutional Investors Weigh In On Organogenesis

Several hedge funds have recently modified their holdings of ORGO. Verition Fund Management LLC raised its stake in Organogenesis by 542.8% in the third quarter. Verition Fund Management LLC now owns 78,690 shares of the company’s stock worth $225,000 after buying an additional 66,448 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Organogenesis by 19.6% in the 2nd quarter. Dimensional Fund Advisors LP now owns 2,036,743 shares of the company’s stock worth $5,702,000 after acquiring an additional 333,123 shares in the last quarter. AQR Capital Management LLC lifted its stake in shares of Organogenesis by 76.9% during the 2nd quarter. AQR Capital Management LLC now owns 2,268,760 shares of the company’s stock worth $6,353,000 after purchasing an additional 986,132 shares during the last quarter. Cubist Systematic Strategies LLC boosted its position in Organogenesis by 1,350.3% during the second quarter. Cubist Systematic Strategies LLC now owns 94,705 shares of the company’s stock valued at $265,000 after purchasing an additional 88,175 shares in the last quarter. Finally, Acadian Asset Management LLC grew its stake in Organogenesis by 2.4% in the second quarter. Acadian Asset Management LLC now owns 3,074,375 shares of the company’s stock valued at $8,605,000 after purchasing an additional 72,696 shares during the last quarter. Hedge funds and other institutional investors own 49.57% of the company’s stock.

About Organogenesis

Organogenesis Holdings Inc, a regenerative medicine company, develops, manufactures, and commercializes solutions for the advanced wound care, and surgical and sports medicine markets in the United States. The company's advanced wound care products include Affinity, an amniotic membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Novachor, a chorion membrane in which viable cells, growth factors/cytokines, and ECM proteins in the native tissue are preserved; Apligraf, a bioengineered living cell therapy that produce spectrum of cytokines and growth factors; Dermagraft, a bioengineered product that produces human collagen, ECM, proteins, cytokines, and growth factors; NuShield, dehydrated placental tissue covering amnion and chorion membranes for spongy/intermediate layer intact; and PuraPly AM, an antimicrobial barrier that enables conformability and fluid drainage.